| DB ID | MyCo_4121 |
| Title | Prognostic significance of serum antioxidant parameters in immunocompetent patients with cryptococcal meningitis |
| Year | 2012 |
| PMID | 22391756 |
| Fungal Diseases involved | Cryptococcal meningitis |
| Associated Medical Condition | Immunocompetent patients |
| Genus | Cryptococcus |
| Species | neoformans |
| Organism | Cryptococcus neoformans |
| Ethical Statement | Data collection was approved by the institution’s ethics committee, the Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, Guangzhou, Guangdong, 510630, China |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Bilirubin |
| Biomarker Full Name | Bilirubin |
| Biomarker Type | Negative |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | Here retrospectively reviewed the medical records of adult immunocompetent patients (over 15 years of age) with CM from January 2000 to December 2010 admitted to the Third Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, and 94 patients were included in this study. The 94 patients included 73 males and 21 females. |
| Cohort No. | 94 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Cryptococcal meningitis (CM) is the most common fungal infection involving the central nervous system (CNS) and results in a high morbidity and mortality rate, despite vigorous antifungal treatment among human immunodeficiency virus (HIV)-positive patients. However, CM also occurs in non-HIV patients who are immunodeficient due to diabetes, cancer, solid organ transplants, chemotherapeutic drugs, he- matological malignancies, etc. and in healthy individuals with no obvious predisposing factors. Some reports revealed that 10–40% of HIV-negative patients with CM have no apparent immune deficiency. |
| Technique | Immunological assay |
| Analysis Method | Immunological Assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Immunological Assay |
| Up Regulation Down Regulation | Negative |
| Sequence Data | None |
| External Link | None |
